Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) FCF Margin (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed FCF Margin for 14 consecutive years, with 34.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 4963.0% year-over-year to 34.71%, compared with a TTM value of 51.6% through Dec 2025, up 3628.0%, and an annual FY2025 reading of 51.6%, up 3628.0% over the prior year.
  • FCF Margin was 34.71% for Q4 2025 at Karyopharm Therapeutics, down from 13.3% in the prior quarter.
  • Across five years, FCF Margin topped out at 20.01% in Q4 2021 and bottomed at 246.66% in Q2 2021.
  • Average FCF Margin over 5 years is 86.38%, with a median of 79.27% recorded in 2022.
  • The sharpest move saw FCF Margin tumbled -12643bps in 2021, then soared 15809bps in 2022.
  • Year by year, FCF Margin stood at 20.01% in 2021, then plummeted by -499bps to 79.94% in 2022, then surged by 31bps to 55.07% in 2023, then crashed by -53bps to 84.33% in 2024, then soared by 59bps to 34.71% in 2025.
  • Business Quant data shows FCF Margin for KPTI at 34.71% in Q4 2025, 13.3% in Q3 2025, and 49.29% in Q2 2025.